Publications
Print PDF
Amgen Ruling Could Prevent Slowdowns in Biosimilar Market Entry
July 6, 2020
Valerie Bauman
Bloomberg Law

Axinn partner Chad Landmon was quoted in the Bloomberg Law article, "Amgen Ruling Could Prevent Slowdowns in Biosimilar Market Entry."

Click here to access the article. 

By using the Axinn, Veltrop & Harkrider LLP website with cookies enabled on your browser, you agree to our use of cookies during your browsing experience. Learn more about our privacy policy.